RxDoctor Payments Data

Angela Lopez, PA

Medical · New York, NYNPI 1881237576

Payments from drug & device makers

$1,659in general payments, 2019–2025

Across 65 payments — averaging $25.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$498
  • Urogen Pharma, Inc.$211
  • Endo USA, Inc.$141
  • Procept Biorobotics Corporation$127
  • Teleflex LLC$117
  • AbbVie$104
  • plus $460 from 10 others

What the payments were for

  • Food & beverage$1,659100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,659 in reported general payments places this provider in the 75th percentile of 2,395 medical providers in New York.

See all medical providers in New York

Medicare billing

Part B allowed, 2024
$15,566
Medicare patients
54
Services billed
211

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron257$138,206
Testosterone77$30,637
MyrbetriqMirabegron46$21,371
Tamsulosin Hcl899$12,633
Estradiol146$7,235
Alfuzosin Hcl ErAlfuzosin Hcl448$4,779
Solifenacin Succinate66$4,637
Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl29$3,553
Finasteride321$2,727
Silodosin45$2,418
Oxybutynin Chloride ErOxybutynin Chloride64$939
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip34$812
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst59$702
Levofloxacin39$411
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav45$216

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$498$138,206257 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,395 medical providers in New York.

Other medical in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →